CEO Update - 18 March 2024
A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future.
Member spotlight: Meet OMass Therapeutics
In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business Council, shares how the company is pioneering new approaches to drug discovery, targeting challenging diseases with their advanced platform.
Prix Galien UK 2024 – award nominations and forum tickets live
The Prix Galien Award recognises outstanding achievements in improving the global human condition through the development of innovative drugs and treatments.
Coulter Partners DEI: Views from leadership series - Lene Gerlach
In the latest instalment of our Diversity, Equity & Inclusion Leadership series, we spoke to Lene Gerlach, Founder and Chair of Women in Life Science Denmark (WiLD), and Partner at Eir Ventures, a Nordic Life Science Venture Fund.
Coulter Partners DEI: Views from leadership series - Yael Gruenbaum-Cohen
In the latest instalment of our Diversity, Equity & Inclusion Leadership series, we spoke to Dr. Yael Gruenbaum-Cohen, Partner at aMoon, a global Health Tech and Life Sciences investment fund and Founder of WE@HealthTech, a programme for female leadership talent in Health Tech.
FemTech and Women’s Health start-ups urged to join Discovery Park’s growth programme
Discovery Park, Kent’s thriving life science community, has launched a special edition of their growth and support programme, Discovery Spark, for start-ups in FemTech and Women’s Health.
NCIMB Ltd and GitLife win Innovate UK funding to support development of new therapeutic solutions
Aberdeen-based biotechnology company NCIMB is teaming up with innovative Newcastle University Spinout GitLife Biotech in a 12-month project that will investigate the therapeutic potential of gut microbes.
Relation Therapeutics secures $35 million of new seed financing led by DCVC
Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
Female leaders discuss their career journeys for International Women’s Day 2024 at SBC
Over 80 guests from across the biotech industry came to Stevenage Bioscience Catalyst to enjoy talks and networking with female leaders in celebration of International Women’s Day 2024 with the theme of ‘Inspire Inclusion.’
Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda
Moa Technology, the leading agricultural biotech company, and Croda International plc, the global life sciences and consumer care company, have formed a strategic partnership to tackle the global problem of declining food crop yields by using marine science.